Loading clinical trials...

Rifaximin Therapy in Chronic Kidney Disease | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Rifaximin Therapy in Chronic Kidney Disease

Impact of Rifaximin Therapy on Intestinal Byproducts in Chronic Kidney Disease

NCT02342639•Jason Stubbs, MD

Summary

The purpose of this study is to determine if Rifaximin decreases serum and urine levels of bacterial byproducts and inflammatory markers in patients with chronic kidney disease and to evaluate changes in the bacterial content of the stool from these individuals.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Chronic kidney disease with eGFR ≤ 39 ml/min/1.73m2

Exclusion Criteria

•Patients with normal renal function or those with less advanced kidney disease
•Inability or unwillingness to provide consent
•Patients undergoing hemodialysis or peritoneal dialysis therapy or those who have undergone organ transplant
•Patients who may be pregnant
•Hemodynamically unstable patients
•Patients with liver failure, pancreatic insufficiency, or inflammatory bowel disease
•Patients with ongoing or recent infection and those with history of C-diff infection
•Patients with abnormal bowel structure secondary to surgical or anatomic variations
•Patients on certain medications including immunosuppressants, antidiarrheal agents, bile acid sequestrants and current or recent (within the last 3 months) use of antibiotics

Locations (1)

University of Kansas Medical Center

Kansas City, Kansas, United States

Key Dates

Start Date

June 1, 2015

Primary Completion Date

March 1, 2019

Completion Date

March 1, 2019

Last Updated

November 5, 2021

Enrollment

ACTUAL participants

Conditions

Chronic Kidney Disease

Interventions

Rifaximin

DRUG

Placebo

DRUG

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390

Atherosclerosis Cardiovascular DiseaseChronic Kidney Disease

View study

RECRUITINGPHASE2

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

NCT06926660

Chronic Kidney Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 5, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Rifaximin Therapy in Chronic Kidney Disease

Inclusion Criteria

Exclusion Criteria

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis